Guggenheim raises Elevance stock price target on earnings execution By Investing.com

Guggenheim raised Elevance Health’s price target to $399 from $396 while keeping a Buy rating, implying about 15% upside from the $346 share price. The call follows strong Q1 2026 results, with adjusted EPS of $12.58 versus $10.84 expected and revenue of $49.5 billion versus $48.2 billion expected, alongside continued buybacks and margin-improvement efforts in Medicaid. Additional analyst target increases from Leerink, Barclays, and Evercore reinforce a constructive view on execution and earnings recovery.

Analysis

The real signal here is not the target raise itself but the market’s willingness to pay for a cleaner earnings path in managed care despite ongoing regulatory overhangs. ELV is showing that margin recovery can come from mix and acuity normalization rather than top-line heroics, which matters because it is easier to defend in a slowing utilization environment than a revenue-led story. If this holds, the next leg of multiple expansion should come from investors treating the name less like a policy beta and more like a self-help compounder.

Second-order, stronger ELV execution is a warning shot for peers with weaker Medicaid operating leverage: it raises the bar for how much discount the market is willing to give to carriers citing “transitory” headwinds. The share repurchase angle is important because buybacks at this valuation create a non-linear EPS effect if margins stabilize, effectively pulling forward part of the 2027 compounding story into 2026. That said, the same leverage cuts both ways: if the CMS issue turns from nuisance to earnings constraint, the market will re-rate the whole group faster than consensus expects.

The consensus may be underestimating how much of the near-term upside is already in the quarter, while underappreciating how durable the capital return program is if free cash flow remains around current levels. The cleaner contrarian is that the stock may not need a big fundamental surprise to work; it only needs the absence of incremental regulatory bad news plus one or two more quarters of stable medical cost trends. In that scenario, a mid-teens upside target could prove conservative rather than ambitious over a 3-6 month horizon.

Key Decisions for Investors

• Long ELV on pullbacks over the next 1-4 weeks; target a 10-15% move over 3-6 months if Medicaid margin improvement persists and CMS risk remains contained.
• Pair trade: long ELV / short a weaker managed-care or Medicaid-sensitive peer basket for 2-3 quarters; the trade benefits from execution dispersion and should outperform if the market rewards buyback-backed EPS compounding.
• Use ELV call spreads 3-6 months out to express upside with defined risk; structure for a modest continuation move rather than a squeeze, since much of the headline catalyst is already known.
• Trim or avoid chasing after sharp upside days; the better entry is after any regulatory headline-driven air pocket, because the key catalyst is operational follow-through rather than a one-day estimate reset.
• Watch for any deterioration in CMS commentary or medical cost trend data as the primary reversal trigger; if either worsens, de-risk quickly because the stock’s rerating depends on multiple expansion, not just earnings delivery.